Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Researchers from the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are part of an international team ...

Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar ® (TLD-1433) in patients with Bacillus ...

A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in ...

WASHINGTON -- The gene therapy nadofaragene firadenovec (Adstiladrin) continued to demonstrate clinical activity in patients with high-risk bladder cancer, researchers reported. The long-term ...

ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrangement with the Serum Institute of India, the world’s ...

Credit: Getty Images. 5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. Use of 5α-reductase inhibitors (5-ARIs) prior to a bladder ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...